


Fewer false positives. Fewer unnecessary amnios.

For every 1000 patients screened, MaterniT21™ Plus would report 6 false positives while Panorama would report 1, according to validation studies.

FALSE POSITIVE RATE: T21, T18, T13¹



PANORAMA ADDRESSES COMMON CAUSES OF FALSE POSITIVES:

- Vanishing Twin


Panorama is the only NIPT capable of detecting VT. With MaterniT21™, 1 out of 3 false positives were attributed to VT.²

- Maternal contribution

By separately analyzing the maternal genotype Panorama recognizes relevant maternal genetic abnormalities and avoids incorrectly attributing them to the fetus.

Lower false negative rate.

FALSE NEGATIVE RATE: T21, T18, T13¹



PANORAMA ADDRESSES COMMON CAUSES OF FALSE NEGATIVES:

- Low fetal fraction


Panorama measures fetal fraction and adjusts its algorithm accordingly. MaterniT21™ sensitivity falls to 75% at fetal fractions below 8%.³

- Triploidy

Only Panorama detects triploidy because it is not dependent on a reference chromosome.

No incorrect calls on gender in validation studies.

ERROR RATES IN FETAL SEX DETERMINATION IN VALIDATION STUDIES^{5,6}



- Fetal sex is requested in 85% of Panorama cases.⁴

A wrong call can create anxiety for the patient and lead to unnecessary additional clinical work-up.

- With MaterniT21™, 1 out of 150 may report gender incorrectly.

Higher accuracy for microdeletions.^{4,7}

		MaterniT21™ Plus	Panorama™
Sensitivity	22q	60-86%	95.7% (45/47)
	Prader Willi	60-86%	93.8% (15/16)
	Angelman	60-86%	95.5% (21/22)
	1p36	60-86%	100% (1/1)
	Cri-du-Chat	85-90%	100% (24/24)
Qualitative Attributes	Detect uniparental disomy	NO	YES
	Detect mother's status	NO	YES
Standards	New York State License for 22q (conditional)	NO	YES

Appropriate for all patients regardless of pregnancy risk.

Panorama has been proven to be effective in both high- and low-risk pregnancies.^{5,9} MaterniT21™ is offered only for increased risk pregnancies.

Panorama Validation Study		
Cohort	Sens	Spec
High risk (35+ years old)	98.0% (98/100)	99.5% (389/391)
Low risk (<35 years old)	100% (5/5)	100% (469/469)

Panorama Clinical Outcomes Study	
Cohort (High risk call %)	PPV (T21, T18, T13, MX combined)
≥35 (2.5%)	82.9%
<35 (1.2%)	87.2%

Personalized results for easier patient counseling.

- Panorama results are reported as a personalized risk score, along with fetal fraction.
- MaterniT21™ reports results as “positive” or “negative”, making it challenging to counsel patients on high risk results.

Panorama is the only NIPT that distinguishes between fetal and maternal DNA.

- Leveraging a SNP-based approach and powered by Natera's proprietary NATUS algorithm, Panorama delivers the most accurate results for the common aneuploidies and a panel of clinically significant microdeletion syndromes.

References:

For a list of complete citations please visit <http://www.panoramatest.com/comp1>.



Panorama:
part of the Natera
family of products



201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1-855-866-NIPT (6478) | Fax 1-650-730-2272
CAP accredited, ISO 13485 and CLIA certified

These tests were developed by Natera, Inc. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA).
©Natera 2014 All Rights Reserved

Note: Natera™ and Panorama™ are trademarks of Natera, Inc.; MaterniT21™ is a trademark of Sequenom, Inc.